ClinicalTrials.gg
CompletedNCT00355030PhoenixUpdated Sep 30, 2019Results posted

Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature

A Phase 3 interventional study of somatropin and leuprorelin in Idiopathic Short Stature (ISS), sponsored by Eli Lilly and Company. Completed at 19 sites in 2 countries. Open to participants aged 8 Years to 171 Months. Per ClinicalTrials.gov, last updated 2019-09-30.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
8 Years to 171 Months
Sex
All
01

Study summary

The present randomized trial was initially intended to study the benefits of a combined treatment with growth hormone (GH) and a gonadotropin-releasing hormone (GnRH) agonist for pubertal children with idiopathic short stature. However, treatments were stopped in January 2012 at the request of the French drug agency. Therefore, a protocol amendment divided the study in two study periods.

Study Period 1 involved combined treatment with somatropin and leuprorelin or treatment with somatropin alone. Participants from France who participated in this Period 1 of the study were asked to participate in a long term safety follow up defined as a Period 2 of the study. Participants from the Netherlands were offered participation in Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS, clinicaltrials.gov Identifier: NCT01088412) for long term safety follow up independent of this study.

02

Conditions studied

  • Idiopathic Short Stature (ISS)
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.

Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 171 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female children with ISS
  • age greater than or equal to 8 years and less than or equal to 12 years and 3 months for girls and greater than or equal to 9 years and less than or equal to 14 years and 3 months for boys
  • bone age less than or equal to 12.0 years for girls and less than or equal to 14.0 years for boys based on a central reading of an X-ray of the left hand and wrist
  • Pubertal stage B2 and B3 for girls based on the Tanner method
  • Pubertal stage G2 and G3 for boys based on the Tanner method

Exclusion criteria

Exclusion Criteria:

  • Growth hormone deficiency (GHD)
  • Insulin-like growth factor-I levels greater than 3 SDS
  • Chromosomal abnormality diagnosed locally on a karyotype. For girls, the karyotype to eliminate a Turner syndrome, is mandatory
  • Small for gestational age (SGA)
  • Has reached menarche (had her first menstrual period)
  • Have any significant concomitant disease that is likely to interfere with growth or with the study, or is a known to Growth Hormone treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    1

    Drug: somatropin · Drug: leuprorelin

  • Experimental
    2

    Drug: somatropin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Drug-related Adverse Events

    A drug-related AE was an AE that occurred postdose or was present predose and became more severe postdose and was considered to be related to study treatment. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline through End of Study (up to 9 years)

  2. Adult Height Standard Deviation Score (SDS)

    The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

    Time frame: Baseline through End of Study (up to 9 years)

Secondary outcomes

  1. Height Velocity

    Height velocity is the difference between 2 height measurements, divided by years elapsed between measurements.

    Time frame: Baseline through End of Study (up to 9 years)

  2. Height SDS

    SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

    Time frame: Baseline through End of Study (up to 9 years)

  3. Difference Between Adult Height SDS and Target Height SDS

    This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of target height \[calculated as (mother's height (SDS) + father's height (SDS))/2\] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

    Time frame: Baseline through End of Study (up to 9 years)

  4. Difference Between Adult Height SDS and Baseline Predicted Height SDS

    This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline predicted height \[calculated using the Bayley-Pinneau method based on height and bone age\] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

    Time frame: Baseline through End up Study (up to 9 years)

  5. Difference Between Adult Height SDS and Baseline Height SDS

    This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline height for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

    Time frame: Baseline through End up Study (up to 9 years)

  6. Percentage of Children With Normal Adult Height SDS

    Percentage of children with normal adult height SDS (greater than -2 SDS and less than +2 SDS)

    Time frame: Baseline through End of Study (up to 9 years)

  7. Bone Age

    Bone age measured using the X-Ray of left hand and wrist.

    Time frame: Baseline through End of Study (up to 9 years)

07

Results

Posted Oct 18, 2016
Limitations and caveats
No statistical analyses was performed after the early treatment termination. All data represented is descriptive statistics only and no confirmatory conclusions can be drawn from this study.

Participant flow

Study Period 1 Treatment
Participant flow — Study Period 1 Treatment
MilestoneSomatropin and Leuprorelin: Experimental Arm 1Somatropin: Experimental Arm 2
Started4645
Received at least one dose of study drug4543
Completed11
Not completed4544
Withdrew: Adverse event11
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject41
Withdrew: Parent/caregiver decision12
Withdrew: Physician decision01
Withdrew: Sponsor decision3432
Withdrew: Protocol entry criterion not met01
Withdrew: Other26
Study Period 2 Long Term Follow-Up
Participant flow — Study Period 2 Long Term Follow-Up
MilestoneSomatropin and Leuprorelin: Experimental Arm 1Somatropin: Experimental Arm 2
Started2019
Completed1917
Not completed12
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryNumber of Participants With One or More Drug-related Adverse Events

A drug-related AE was an AE that occurred postdose or was present predose and became more severe postdose and was considered to be related to study treatment. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline through End of Study (up to 9 years)
Reported as:
Number · participants
Number of Participants With One or More Drug-related Adverse Events
participantsSomatropin and LeuprorelinSomatropin
Study Period 1 (n=46, 45)4238
Study Period 2 (n=20, 19)119
PrimaryAdult Height Standard Deviation Score (SDS)

The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

Time frame:
Baseline through End of Study (up to 9 years)
Reported as:
Mean · standard deviation score
Adult Height Standard Deviation Score (SDS)
standard deviation scoreSomatropin and LeuprorelinSomatropin
Adult Height Standard Deviation Score (SDS)-1.8 ± 0.53-1.9 ± 0.77
SecondaryHeight Velocity

Height velocity is the difference between 2 height measurements, divided by years elapsed between measurements.

Time frame:
Baseline through End of Study (up to 9 years)
Reported as:
Mean · centimeter per year
Height Velocity
centimeter per yearSomatropin and LeuprorelinSomatropin
Randomization (n=45, 43)7.8 ± 6.927.4 ± 6.03
Month 3 (n=45, 43)9.9 ± 3.9410.6 ± 3.53
Month 6 (n=45, 42)8.1 ± 2.319.7 ± 2.80
Month 12 (n=44, 42)7.0 ± 1.648.8 ± 2.33
Month 18 (n=42, 42)6.6 ± 1.688.4 ± 2.64
Month 24 (n=37, 41)4.9 ± 1.337.8 ± 3.36
Month 30 (n=25, 25)6.2 ± 2.095.8 ± 2.93
Month 36 (n=18, 19)6.6 ± 3.253.5 ± 2.71
Month 42 (n=13, 14)5.7 ± 1.943.7 ± 2.17
Month 48 (n=7, 8)5.4 ± 2.272.9 ± 2.73
Month 54 (n=1, 1)6.3 ± 07.1 ± 0
Safety follow up 6 months (n=16, 9)4.6 ± 2.084.5 ± 2.45
Safety follow up 12 months(n=15, 8)2.9 ± 2.372.3 ± 1.43
Safety follow up 18 months (n=12, 4)3.3 ± 1.691.2 ± 1.20
Safety follow up 24 months (n=9, 1)2.0 ± 1.322.5 ± 0
Safety follow up 36 months (n=5, 0)1.3 ± 0.530 ± 0
Safety follow up 42 months (n=2, 0)2.1 ± 2.450 ± 0
Safety follow up 12 months (final height)(n=18,14)0.5 ± 0.860.8 ± 1.59
Safety follow up 24 months (final height) (n=7,10)0.3 ± 0.770.3 ± 0.97
Safety follow up 36 months (final height) (n=3,7)0.9 ± 0.780.3 ± 0.60
SecondaryHeight SDS

SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

Time frame:
Baseline through End of Study (up to 9 years)
Reported as:
Mean · standard deviation score
Height SDS
standard deviation scoreSomatropin and LeuprorelinSomatropin
Randomization (n=45, 43)-2.5 ± 0.45-2.5 ± 0.46
Month 3 (n=45, 43)-2.4 ± 0.42-2.4 ± 0.47
Month 6 (n=45, 42)-2.3 ± 0.48-2.2 ± 0.52
Month 12 (n=44, 42)-2.2 ± 0.50-2.0 ± 0.57
Month 18 (n=42, 42)-2.2 ± 0.53-1.9 ± 0.63
Month 24 (n=37, 41)-2.3 ± 0.58-1.8 ± 0.67
Month 30 (n=25, 25)-2.2 ± 0.63-2.0 ± 0.58
Month 36 (n=18, 19)-2.0 ± 0.65-2.0 ± 0.68
Month 42 (n=13, 14)-1.8 ± 0.68-1.9 ± 0.66
Month 48 (n=7, 8)-1.6 ± 0.52-1.9 ± 0.65
Month 54 (n=1, 1)-1.0 ± 0-1.7 ± 0
Safety follow up 6 months (n=16, 9)-2.1 ± 0.65-1.7 ± 0.77
Safety follow up 12 months(n=15, 8)-1.9 ± 0.55-1.7 ± 0.77
Safety follow up 18 months (n=12, 4)-1.9 ± 0.63-1.9 ± 0.78
Safety follow up 24 months (n=9, 1)-1.9 ± 0.46-1.2 ± 0
Safety follow up 36 months (n=5, 0)-1.9 ± 0.670 ± 0
Safety follow up 42 months (n=2, 0)-2.4 ± 0.180 ± 0
Safety follow up 12 months (final height)(n=18,14)-1.9 ± 0.46-1.8 ± 0.71
Safety follow up 24 months (final height) (n=7,10)-1.6 ± 0.56-2.0 ± 0.79
Safety follow up 36 months (final height) (n=3,7)-1.2 ± 0.90-2.2 ± 0.94
SecondaryDifference Between Adult Height SDS and Target Height SDS

This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of target height \[calculated as (mother's height (SDS) + father's height (SDS))/2\] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

Time frame:
Baseline through End of Study (up to 9 years)
Reported as:
Mean · standard deviation score
Difference Between Adult Height SDS and Target Height SDS
standard deviation scoreSomatropin and LeuprorelinSomatropin
Difference Between Adult Height SDS and Target Height SDS-0.6 ± 0.89-1.2 ± 0.80
SecondaryDifference Between Adult Height SDS and Baseline Predicted Height SDS

This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline predicted height \[calculated using the Bayley-Pinneau method based on height and bone age\] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

Time frame:
Baseline through End up Study (up to 9 years)
Reported as:
Mean · standard deviation score
Difference Between Adult Height SDS and Baseline Predicted Height SDS
standard deviation scoreSomatropin and LeuprorelinSomatropin
Difference Between Adult Height SDS and Baseline Predicted Height SDS1.1 ± 0.961.2 ± 0.70
SecondaryDifference Between Adult Height SDS and Baseline Height SDS

This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline height for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

Time frame:
Baseline through End up Study (up to 9 years)
Reported as:
Mean · standard deviation score
Difference Between Adult Height SDS and Baseline Height SDS
standard deviation scoreSomatropin and LeuprorelinSomatropin
Difference Between Adult Height SDS and Baseline Height SDS0.6 ± 0.590.6 ± 0.67
SecondaryPercentage of Children With Normal Adult Height SDS

Percentage of children with normal adult height SDS (greater than -2 SDS and less than +2 SDS)

Time frame:
Baseline through End of Study (up to 9 years)
Reported as:
Number · percentage of participants
Percentage of Children With Normal Adult Height SDS
percentage of participantsSomatropin and LeuprorelinSomatropin
Percentage of Children With Normal Adult Height SDS26.725.6
SecondaryBone Age

Bone age measured using the X-Ray of left hand and wrist.

Time frame:
Baseline through End of Study (up to 9 years)
Reported as:
Mean · years
Bone Age
yearsSomatropin and LeuprorelinSomatropin
Randomization (n=45, 43)10.8 ± 1.5811.0 ± 1.45
Month 12 (n=40, 41)11.7 ± 1.5912.1 ± 1.12
Month 24 (n=34, 37)12.4 ± 1.3213.4 ± 1.09
Month 36 (n=18, 18)13.3 ± 1.4914.5 ± 1.64
Month 48 (n=7, 8)14.8 ± 1.3315.4 ± 1.27
Safety follow up 6 months (n=16, 7)14.1 ± 1.1114.9 ± 0.81
Safety follow up 18 months (n=12, 3)15.2 ± 1.2517.0 ± 1.00
Safety follow up 36 months (n=5, 0)15.7 ± 1.040 ± 0
Safety follow up 12 months (final height)(n=18,14)19.6 ± 14.5316.3 ± 1.27

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Somatropin and Leuprorelin—12/46 (26.1%)41/46 (89.1%)
Somatropin—7/45 (15.6%)36/45 (80%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventSomatropin and LeuprorelinSomatropin
AppendicitisInfections and infestations2/462/45
Congenital genital malformationCongenital, familial and genetic disorders0/461/45
GastroenteritisInfections and infestations0/461/45
Viral infectionInfections and infestations0/461/45
AgitationPsychiatric disorders0/461/45
Intentional self-injuryPsychiatric disorders0/461/45
Mental disorderPsychiatric disorders0/461/45
Suicidal ideationPsychiatric disorders0/461/45
NephrolithiasisRenal and urinary disorders0/461/45
Thyroglossal cystCongenital, familial and genetic disorders1/460/45
Most frequent other events
Showing 10 of 30
Most frequent other events
EventSomatropin and LeuprorelinSomatropin
HeadacheNervous system disorders21/4616/45
NasopharyngitisInfections and infestations19/468/45
InfluenzaInfections and infestations15/469/45
GastroenteritisInfections and infestations11/466/45
Injection site painGeneral disorders8/460/45
Abdominal painGastrointestinal disorders4/467/45
ArthralgiaMusculoskeletal and connective tissue disorders7/464/45
CoughRespiratory, thoracic and mediastinal disorders3/466/45
TonsillitisInfections and infestations6/465/45
PyrexiaGeneral disorders4/465/45

Baseline characteristics

The full analysis set (FAS) includes all data from all randomized patients receiving at least one dose of the study drug according to the treatment to which the patients were assigned and with at least one follow-up visit.

Age, Continuous
Age, Continuous(years)Somatropin and LeuprorelinSomatropinTotal
Mean12.1 ± 1.4112.1 ± 1.3312.1 ± 1.36
Sex: Female, Male
Sex: Female, Male(Participants)Somatropin and LeuprorelinSomatropinTotal
Female262046
Male192342
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Somatropin and LeuprorelinSomatropinTotal
American Indian or Alaska Native000
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American101
White384078
More than one race000
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(participants)Somatropin and LeuprorelinSomatropinTotal
Netherlands6511
France393877
Standing Height SDS
Standing Height SDS(Standard Deviation Score)Somatropin and LeuprorelinSomatropinTotal
Mean-2.5 ± 0.45-2.5 ± 0.46-2.5 ± .045
Standing Height
Standing Height(centimeters)Somatropin and LeuprorelinSomatropinTotal
Mean131.6 ± 6.72131.6 ± 5.78131.6 ± 6.24
08

Study locations

19 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Amiens, 80084, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Besancon, 25030, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bordeaux, 33076, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boulogne, 92100, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Le Havre, 76083, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, 59037, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69322, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13385, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nice, 06200, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75743, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reims, 51092, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rennes, 35056, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rouen, 76036, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint-Etienne, 42055, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Strasbourg, 67 098, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tarbes, 65000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toulouse, 31026, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nijmegen, 6525 GM, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rotterdam, 3015 GD, Netherlands
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2006
First posted
Jul 20, 2006
Start
Jun 2006
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Oct 18, 2016
Last update
Sep 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00355030
Responsible party
Sponsor
First posted
Jul 20, 2006
Start date
Jun 2006
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Oct 18, 2016
Last update
Sep 30, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion